Case Study: Neuropsychiatric Symptoms Associated With the Antimalarial Agent Mefloquine
The development of acute neuropsychiatric symptoms in a 10-year-old boy subsequent to his return from travel abroad in Africa, where he had taken the antimalarial agent mefloquine (Lariam®), is reported. A 4-week course of cognitive-behavioral therapy was used to effectively treat this substance-ind...
Gespeichert in:
| Veröffentlicht in: | Journal of the American Academy of Child and Adolescent Psychiatry 1997-11, Vol.36 (11), p.1606-1608 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1608 |
|---|---|
| container_issue | 11 |
| container_start_page | 1606 |
| container_title | Journal of the American Academy of Child and Adolescent Psychiatry |
| container_volume | 36 |
| creator | Clattenburg, Richard N. Donnelly, Craig L. |
| description | The development of acute neuropsychiatric symptoms in a 10-year-old boy subsequent to his return from travel abroad in Africa, where he had taken the antimalarial agent mefloquine (Lariam®), is reported. A 4-week course of cognitive-behavioral therapy was used to effectively treat this substance-induced anxiety disorder, which had been caused by treatment with mefloquine. A review of the literature about adverse neuropsychiatric effects of mefloquine and the differential diagnosis of malaria is provided. In an age in which international travel is occurring with increasing frequency, it is important to obtain travel histories, including exposure to prophylactic medication, when patients present with acute-onset psychiatric symptoms. |
| doi_str_mv | 10.1016/S0890-8567(09)66572-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_212590119</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0890856709665722</els_id><sourcerecordid>25660763</sourcerecordid><originalsourceid>FETCH-LOGICAL-c364t-5133fe8edf63d8c46a3f91ae7421f6fd7cd4626ac4190796c278fc84c0a011da3</originalsourceid><addsrcrecordid>eNqFkE1rGzEQhkVoSZ20PyEgSg_NYVtJq9VHL8WYJimkycEtOQpFGtUK611H0hb876vYxtecBmaemXl5ELqg5AslVHxdEqVJozohPxN9KUQnWcNO0Ix2TDYdp-oNmh2Rd-gs5ydCCJVKnaJT3WquuZyhh4XNgJdl8ttv-A6mNG7y1q2iLSk6vNyuN2VcZzzPeXS1CR4_xLLCZQV4PpS4tr1N0fZ4_heGgn9B6MfnKQ7wHr0Nts_w4VDP0Z-rH78XN83t_fXPxfy2ca3gpelo2wZQ4INovXJc2DZoakFyRoMIXjrPBRPWcaqJ1MIxqYJT3BFLKPW2PUcf93c3qT6GXMzTOKWhvjSMsk5XSleo20MujTknCGaTavS0NZSYF5lmJ9O8mDJEm51Mw-rexeH49LgGf9w62KvzT4e5zc72IdnBxXzEGOlassO-7zGoIv5FSCa7CIMDHxO4YvwYXwnyH5ntkP4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>212590119</pqid></control><display><type>article</type><title>Case Study: Neuropsychiatric Symptoms Associated With the Antimalarial Agent Mefloquine</title><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>Journals@Ovid Complete</source><creator>Clattenburg, Richard N. ; Donnelly, Craig L.</creator><creatorcontrib>Clattenburg, Richard N. ; Donnelly, Craig L.</creatorcontrib><description>The development of acute neuropsychiatric symptoms in a 10-year-old boy subsequent to his return from travel abroad in Africa, where he had taken the antimalarial agent mefloquine (Lariam®), is reported. A 4-week course of cognitive-behavioral therapy was used to effectively treat this substance-induced anxiety disorder, which had been caused by treatment with mefloquine. A review of the literature about adverse neuropsychiatric effects of mefloquine and the differential diagnosis of malaria is provided. In an age in which international travel is occurring with increasing frequency, it is important to obtain travel histories, including exposure to prophylactic medication, when patients present with acute-onset psychiatric symptoms.</description><identifier>ISSN: 0890-8567</identifier><identifier>EISSN: 1527-5418</identifier><identifier>DOI: 10.1016/S0890-8567(09)66572-2</identifier><identifier>PMID: 9394947</identifier><identifier>CODEN: JAAPEE</identifier><language>eng</language><publisher>Hagerstown, MD: Elsevier Inc</publisher><subject>antimalarial ; Antimalarials - adverse effects ; anxiety ; Anxiety Disorders - chemically induced ; Anxiety Disorders - diagnosis ; Anxiety Disorders - therapy ; Biological and medical sciences ; Child ; Child psychology ; Cognitive Therapy ; Diagnosis, Differential ; Drug therapy ; Drug toxicity and drugs side effects treatment ; Humans ; Malaria ; Malaria - prevention & control ; Male ; Medical sciences ; mefloquine (Lariam®) ; Mefloquine - adverse effects ; Mental disorders ; Neurology ; Pharmacology. Drug treatments ; Toxicity: nervous system and muscle ; Travel</subject><ispartof>Journal of the American Academy of Child and Adolescent Psychiatry, 1997-11, Vol.36 (11), p.1606-1608</ispartof><rights>1997 The American Academy of Child and Adolescent Psychiatry</rights><rights>1998 INIST-CNRS</rights><rights>Copyright Lippincott Williams & Wilkins Nov 1997</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c364t-5133fe8edf63d8c46a3f91ae7421f6fd7cd4626ac4190796c278fc84c0a011da3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0890856709665722$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,30976,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2053047$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9394947$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Clattenburg, Richard N.</creatorcontrib><creatorcontrib>Donnelly, Craig L.</creatorcontrib><title>Case Study: Neuropsychiatric Symptoms Associated With the Antimalarial Agent Mefloquine</title><title>Journal of the American Academy of Child and Adolescent Psychiatry</title><addtitle>J Am Acad Child Adolesc Psychiatry</addtitle><description>The development of acute neuropsychiatric symptoms in a 10-year-old boy subsequent to his return from travel abroad in Africa, where he had taken the antimalarial agent mefloquine (Lariam®), is reported. A 4-week course of cognitive-behavioral therapy was used to effectively treat this substance-induced anxiety disorder, which had been caused by treatment with mefloquine. A review of the literature about adverse neuropsychiatric effects of mefloquine and the differential diagnosis of malaria is provided. In an age in which international travel is occurring with increasing frequency, it is important to obtain travel histories, including exposure to prophylactic medication, when patients present with acute-onset psychiatric symptoms.</description><subject>antimalarial</subject><subject>Antimalarials - adverse effects</subject><subject>anxiety</subject><subject>Anxiety Disorders - chemically induced</subject><subject>Anxiety Disorders - diagnosis</subject><subject>Anxiety Disorders - therapy</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Child psychology</subject><subject>Cognitive Therapy</subject><subject>Diagnosis, Differential</subject><subject>Drug therapy</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Humans</subject><subject>Malaria</subject><subject>Malaria - prevention & control</subject><subject>Male</subject><subject>Medical sciences</subject><subject>mefloquine (Lariam®)</subject><subject>Mefloquine - adverse effects</subject><subject>Mental disorders</subject><subject>Neurology</subject><subject>Pharmacology. Drug treatments</subject><subject>Toxicity: nervous system and muscle</subject><subject>Travel</subject><issn>0890-8567</issn><issn>1527-5418</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>7QJ</sourceid><recordid>eNqFkE1rGzEQhkVoSZ20PyEgSg_NYVtJq9VHL8WYJimkycEtOQpFGtUK611H0hb876vYxtecBmaemXl5ELqg5AslVHxdEqVJozohPxN9KUQnWcNO0Ix2TDYdp-oNmh2Rd-gs5ydCCJVKnaJT3WquuZyhh4XNgJdl8ttv-A6mNG7y1q2iLSk6vNyuN2VcZzzPeXS1CR4_xLLCZQV4PpS4tr1N0fZ4_heGgn9B6MfnKQ7wHr0Nts_w4VDP0Z-rH78XN83t_fXPxfy2ca3gpelo2wZQ4INovXJc2DZoakFyRoMIXjrPBRPWcaqJ1MIxqYJT3BFLKPW2PUcf93c3qT6GXMzTOKWhvjSMsk5XSleo20MujTknCGaTavS0NZSYF5lmJ9O8mDJEm51Mw-rexeH49LgGf9w62KvzT4e5zc72IdnBxXzEGOlassO-7zGoIv5FSCa7CIMDHxO4YvwYXwnyH5ntkP4</recordid><startdate>19971101</startdate><enddate>19971101</enddate><creator>Clattenburg, Richard N.</creator><creator>Donnelly, Craig L.</creator><general>Elsevier Inc</general><general>Lippincott</general><general>Elsevier BV</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope><scope>7TK</scope><scope>K9.</scope></search><sort><creationdate>19971101</creationdate><title>Case Study: Neuropsychiatric Symptoms Associated With the Antimalarial Agent Mefloquine</title><author>Clattenburg, Richard N. ; Donnelly, Craig L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c364t-5133fe8edf63d8c46a3f91ae7421f6fd7cd4626ac4190796c278fc84c0a011da3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>antimalarial</topic><topic>Antimalarials - adverse effects</topic><topic>anxiety</topic><topic>Anxiety Disorders - chemically induced</topic><topic>Anxiety Disorders - diagnosis</topic><topic>Anxiety Disorders - therapy</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Child psychology</topic><topic>Cognitive Therapy</topic><topic>Diagnosis, Differential</topic><topic>Drug therapy</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Humans</topic><topic>Malaria</topic><topic>Malaria - prevention & control</topic><topic>Male</topic><topic>Medical sciences</topic><topic>mefloquine (Lariam®)</topic><topic>Mefloquine - adverse effects</topic><topic>Mental disorders</topic><topic>Neurology</topic><topic>Pharmacology. Drug treatments</topic><topic>Toxicity: nervous system and muscle</topic><topic>Travel</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Clattenburg, Richard N.</creatorcontrib><creatorcontrib>Donnelly, Craig L.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Journal of the American Academy of Child and Adolescent Psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Clattenburg, Richard N.</au><au>Donnelly, Craig L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Case Study: Neuropsychiatric Symptoms Associated With the Antimalarial Agent Mefloquine</atitle><jtitle>Journal of the American Academy of Child and Adolescent Psychiatry</jtitle><addtitle>J Am Acad Child Adolesc Psychiatry</addtitle><date>1997-11-01</date><risdate>1997</risdate><volume>36</volume><issue>11</issue><spage>1606</spage><epage>1608</epage><pages>1606-1608</pages><issn>0890-8567</issn><eissn>1527-5418</eissn><coden>JAAPEE</coden><abstract>The development of acute neuropsychiatric symptoms in a 10-year-old boy subsequent to his return from travel abroad in Africa, where he had taken the antimalarial agent mefloquine (Lariam®), is reported. A 4-week course of cognitive-behavioral therapy was used to effectively treat this substance-induced anxiety disorder, which had been caused by treatment with mefloquine. A review of the literature about adverse neuropsychiatric effects of mefloquine and the differential diagnosis of malaria is provided. In an age in which international travel is occurring with increasing frequency, it is important to obtain travel histories, including exposure to prophylactic medication, when patients present with acute-onset psychiatric symptoms.</abstract><cop>Hagerstown, MD</cop><pub>Elsevier Inc</pub><pmid>9394947</pmid><doi>10.1016/S0890-8567(09)66572-2</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0890-8567 |
| ispartof | Journal of the American Academy of Child and Adolescent Psychiatry, 1997-11, Vol.36 (11), p.1606-1608 |
| issn | 0890-8567 1527-5418 |
| language | eng |
| recordid | cdi_proquest_journals_212590119 |
| source | Applied Social Sciences Index & Abstracts (ASSIA); MEDLINE; Elsevier ScienceDirect Journals; Journals@Ovid Complete |
| subjects | antimalarial Antimalarials - adverse effects anxiety Anxiety Disorders - chemically induced Anxiety Disorders - diagnosis Anxiety Disorders - therapy Biological and medical sciences Child Child psychology Cognitive Therapy Diagnosis, Differential Drug therapy Drug toxicity and drugs side effects treatment Humans Malaria Malaria - prevention & control Male Medical sciences mefloquine (Lariam®) Mefloquine - adverse effects Mental disorders Neurology Pharmacology. Drug treatments Toxicity: nervous system and muscle Travel |
| title | Case Study: Neuropsychiatric Symptoms Associated With the Antimalarial Agent Mefloquine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T00%3A32%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Case%20Study:%20Neuropsychiatric%20Symptoms%20Associated%20With%20the%20Antimalarial%20Agent%20Mefloquine&rft.jtitle=Journal%20of%20the%20American%20Academy%20of%20Child%20and%20Adolescent%20Psychiatry&rft.au=Clattenburg,%20Richard%20N.&rft.date=1997-11-01&rft.volume=36&rft.issue=11&rft.spage=1606&rft.epage=1608&rft.pages=1606-1608&rft.issn=0890-8567&rft.eissn=1527-5418&rft.coden=JAAPEE&rft_id=info:doi/10.1016/S0890-8567(09)66572-2&rft_dat=%3Cproquest_cross%3E25660763%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=212590119&rft_id=info:pmid/9394947&rft_els_id=S0890856709665722&rfr_iscdi=true |